Lupus Research Alliance Launches the DREAM Knowledge-Exchange Platform to Accelerate Precision Medicine in Lupus
NEW YORK, NY, November 7, 2024 —
The DREAM is the final component of the Lupus Research Alliance’s Lupus Nexus, an...
Lupus Therapeutics Statement on Positive Data from Phase 3 PHOENYCS GO Trial in Moderate-To-Severe Systemic Lupus
Lupus Therapeutics Statement on Positive Data from Phase 3 PHOENYCS GO Trial in Moderate-To-Severe Systemic Lupus
WASHINGTON, D.C., November 19, 2024 — Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance (LRA), is encouraged by the positive Phase 3 PHOENYCS GO results reported by UCB and Biogen during ACR Convergence 2024. Study sponsors presented results of the pivotal trial designed to evaluate the efficacy and safety of dapirolizumab pegol (DZP) for patients with moderate-to-severe systemic lupus erythematosus (SLE).
The press release reported: “DZP met its primary endpoint, showing statistically and clinically significant improvement across all organ systems as measured by the endpoint BICLA that measures disease activity. A greater response was seen across many clinical endpoints among participants treated with DZP, including 50% less severe disease flares compared to participants on standard of care alone.”
Click here for full statement from Lupus Therapeutics Executive Vice President Stacie Bell, PhD.
Media Contacts:
Penny Mitchell
PMitchell@lupusresearch.org
914-715-6687
Margy Meislin
MMeislin@lupusresearch.org
516-426-6160
The full press release is available on the Lupus Therapeutics website.
